Rather than existing in a planktonic or free-living form, evidence indicates that microbes show a preference for living in a sessile form within complex communities called biofilms. Biofilms appear to afford microbes a survival advantage by optimizing nutrition, offering protection against hostile elements, and providing a network for cell-to-cell signaling and genetic exchange. Biofilms, Infection, and Antimicrobial Therapy provides an in-depth exploration of biofilms, offering broad background information, as well a detailed look at the serious concerns to which biofilm-associated infections give rise. Prosthetic device infections, such as those involving artificial heart valves, intravascular catheters, or prosthetic joints, are prime examples of biofilm-associated infections. With the increasing use of such devices in the modern practice of medicine, the prevalence of these infections is expected to increase. Unfortunately, one of the most troubling characteristics of microbes found in biofilms is a profound resistance to antimicrobial agents. As biofilm-associated infections are particularly difficult to treat, they result in significant mortality, morbidity, and increased economic burden. Clearly, a better understanding of the pathogenesis of these infections and improved means for prevention and treatment are urgently needed! InBiofilms, Infection, and Antimicrobial Therapy, Drs Pace, Rupp, and Finch assemble the contributions of more than 50 of the world's leading authorities on microbial biofilms who present recent findings on antibacterial tolerance and bacterial persistence associated with biofilms and discuses the implications of those findings with regard to human health. They explore the molecular mechanisms of bacterial adherence, biofilm formation, regulation of biofilm maintenance, and cell-to-cell communication and present the latest information on various treatment protocols that should aid physicians in the treatment o

This book will cover both the evidence for biofilms in many chronic bacterial infections as well as the problems facing these infections such as diagnostics and treatment regimes. A still increasing interest and emphasis on the sessile bacterial lifestyle biofilms has been seen since it was realized that that less than 0.1% of the total microbial biomass lives in the planktonic mode of growth. The term was coined in 1978 by Costerton et al. who defined the term biofilm for the first time.In 1993 the American Society for Microbiology (ASM) recognised that the biofilmmode of growth was relevant to microbiology. Lately many articles have been published on the clinical implications of bacterial biofilms. Both original articles and reviews concerning the biofilm problem are available.

Throughout the biological world, bacteria thrive predominantly in surface-attached, matrix-enclosed, multicellular communities or biofilms, as opposed to isolated planktonic cells. This choice of lifestyle is not trivial, as it involves major shifts in the use of genetic information and cellular energy, and has profound consequences for bacterial physiology and survival. Growth within a biofilm can thwart immune function and antibiotic therapy and thereby complicate the treatment of infectious diseases, especially chronic and foreign device-associated infections. Modern studies of many important biofilms have advanced well beyond the descriptive stage, and have begun to provide molecular details of the structural, biochemical, and genetic processes that drive biofilm formation and its dispersion. There is much diversity in the details of biofilm development among various species, but there are also commonalities. In most species, environmental and nutritional conditions greatly influence biofilm development. Similar kinds of adhesive molecules often promote biofilm formation in diverse species. Signaling and regulatory processes that drive biofilm development are often conserved, especially among related bacteria. Knowledge of such processes holds great promise for efforts to control biofilm growth and combat biofilm-associated infections. This volume focuses on the biology of biofilms that affect human disease, although it is by no means comprehensive. It opens with chapters that provide the reader with current perspectives on biofilm development, physiology, environmental, and regulatory effects, the role of quorum sensing, and resistance/phenotypic persistence to antimicrobial agents during biofilm growth.

Nanostructures for Antimicrobial Therapy discusses the pros and cons of the use of nanostructured materials in the prevention and eradication of infections, highlighting the efficient microbicidal effect of nanoparticles against antibiotic-resistant pathogens and biofilms. Conventional antibiotics are becoming ineffective towards microorganisms due to their widespread and often inappropriate use. As a result, the development of antibiotic resistance in microorganisms is increasingly being reported. New approaches are needed to confront the rising issues related to infectious diseases. The merging of biomaterials, such as chitosan, carrageenan, gelatin, poly (lactic-co-glycolic acid) with nanotechnology provides a promising platform for antimicrobial therapy as it provides a controlled way to target cells and induce the desired response without the adverse effects common to many traditional treatments. Nanoparticles represent one of the most promising therapeutic treatments to the problem caused by infectious micro-organisms resistant to traditional therapies. This volume discusses this promise in detail, and also discusses what challenges the greater use of nanoparticles might pose to medical professionals. The unique physiochemical properties of nanoparticles, combined with their growth inhibitory capacity against microbes has led to the upsurge in the research on nanoparticles as antimicrobials. The importance of bactericidal nanobiomaterials study will likely increase as development of resistant strains of bacteria against most potent antibiotics continues. - Shows how nanoantibiotics can be used to more effectively treat disease - Discusses the advantages and issues of a variety of different nanoantibiotics, enabling medics to select which best meets their needs - Provides a cogent summary of recent developments in this field, allowing readers to quickly familiarize themselves with this topic area

This book examines biofilms in nature. Organized into four parts, this book addresses biofilms in wastewater treatment, inhibition of biofilm formation, biofilms and infection, and ecology of biofilms. It is designed for clinicians, researchers, and industry professionals in the fields of microbiology, biotechnology, ecology, and medicine as well as graduate and postgraduate students.

Infections of the bones (osteomyelitis) and joints (septic arthritis) are serious health problems which require antibiotics and often surgery. Awareness among health professionals of the causes and treatment options for various types of bone and joint infections is essential for effective resolution. Bone and Joint Infections takes a multidisciplinary approach in covering the diagnostic and therapeutic treatment of osteomyelitis and septic arthritis, including different types of implant-associated infections. Correct and rapid diagnosis of bone and joint infection is crucial, and requires the input of a variety of specialists. Bone and Joint Infection takes a similarly collaborative and comprehensive approach, including chapters authored by clinicians, laboratory specialists, and surgeons. Covering the basic microbiology and clinical aspects of bone and joint infection, this book will be a valuable resource both for researchers in the lab and for physicians and surgeons seeking a comprehensive reference on osteomyelitis and septic arthritis.

This book provides a survey of recent advances in the development of antibiofilm agents for clinical and environmental applications. The fact that microbes exist in structured communities called biofilms has slowly become accepted within the medical community. We now know that over 80% of all infectious diseases are biofilm-related; however, significant challenges still lie in our ability to diagnose and treat these extremely recalcitrant infections. Written by experts from around the globe, this book offers a valuable resource for medical professionals seeking to treat biofilm-related disease, academic and industry researchers interested in drug discovery and instructors who teach courses on microbial pathogenesis and medical microbiology.